Abstract
BackgroundA novel, rapid, point-of-care urine-based lipoarabinomannan assay (Fujifilm SILVAMP TB LAM (“FujiLAM”)) has previously demonstrated substantially higher sensitivity for tuberculosis (TB) compared with the commercially available Determine TB LAM assay using biobanked specimens. However, FujiLAM has not been prospectively evaluated using fresh urine specimens. Therefore, we determined the diagnostic accuracy of FujiLAM among HIV-positive and HIV-negative outpatients with presumptive TB in Zambia.MethodsAdult (≥18 years old) presumptive TB patients presenting to two outpatient public health facilities in Lusaka were included. All patients submitted sputa samples for smear microscopy, Xpert MTB/RIF and mycobacterial culture, and urine samples for the FujiLAM assay. Microbiologically confirmed TB was defined by the detection of Mycobacterium tuberculosis in sputum using culture; this served as the reference standard to assess the diagnostic accuracy of FujiLAM.Results151 adults with paired sputum microbiological tests and urine FujiLAM results were included; 45% were HIV-positive. Overall, 34 out of 151 (23%) patients had culture-confirmed pulmonary TB. The overall sensitivity and specificity of FujiLAM was 77% (95% CI 59–89%) and 92% (95% CI 86–96%), respectively. FujiLAM's sensitivity among HIV-positive patients was 75% (95% CI 43–95%) compared with 75% (95% CI 51–91%) among HIV-negative patients. The sensitivity of FujiLAM in patients with smear-positive, confirmed pulmonary TB was 87% (95% CI 60–98%) compared with 68% (95% CI 43–87%) among patients with smear-negative, confirmed pulmonary TB.ConclusionsFujiLAM demonstrated high sensitivity for the detection of TB among both HIV-positive and HIV-negative adults, and also demonstrated good specificity despite the lack of systematic extrapulmonary sampling to inform a comprehensive microbiological reference standard.
Funder
German Federal Ministry of Education and Research through Kreditanstalt fur Wiederaufbau
Global Health Innovative Technology Fund
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference16 articles.
1. World Health Organization . High priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. 2014. www.who.int/tb/publications/tpp_report/en Date last accessed: 24 April 2021.
2. World Health Organization . Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV: policy update 2019. 2019. www.who.int/tb/publications/2019/LAMPolicyUpdate2019/en Date last accessed: 24 April 2021.
3. Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli;Hunter;J Biol Chem,1986
4. Point-of-care urine LAM tests for tuberculosis diagnosis: a status update;Bulterys;J Clin Med,2020
5. Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers;Singhroy;Gates Open Res,2020
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献